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Abstract
Background: Genetic renal diseases (GRD) are a heterogeneous and incompletely understood group of disorders
accounting for approximately 10 % of those diagnosed with kidney disease. The advent of Next Generation sequencing
and new approaches to disease modelling may allow the identification and validation of novel genetic variants in
patients with previously incompletely explained or understood GRD.
Methods/Design: This study will recruit participants in families/trios from a multidisciplinary sub-specialty Renal
Genetics Clinic where known genetic causes of GRD have been excluded or where genetic testing is not available. After
informed patient consent, whole exome and/or genome sequencing will be performed with bioinformatics analysis
undertaken using a customised variant assessment tool. A rigorous process for participant data management will
be undertaken. Novel genetic findings will be validated using patient-derived induced pluripotent stem cells via
differentiation to renal and relevant extra-renal tissue phenotypes in vitro. A process for managing the risk of
incidental findings and the return of study results to participants has been developed.
Discussion: This investigator-initiated approach brings together experts in nephrology, clinical and molecular
genetics, pathology and developmental biology to discover and validate novel genetic causes for patients in
Australia affected by GRD without a known genetic aetiology or pathobiology.
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Background
Renal disease is common with reported prevalence ran-
ging from 10 to 16 % of Australian adults [1–3]. The
impact of renal disease on the Australian community in
terms of morbidity, mortality and health service re-
quirements is significant [4, 5]. Renal disease is the
most common cause of hospital admission, with more
than 1,000,000 admissions per year, and the cumulative
cost of treating current and new cases of end stage kid-
ney disease 2009–2020 is estimated at AUD$11.3–12.3
billion [6]. Genetic renal disease (GRD) accounts for
approximately 10 % of patients with renal disease [7, 8],
with an additional proportion not as yet identified as
being GRD or even as having yet developed renal disease.
Up to half of presently identified GRD cases remain gene-
tically unexplained.
The impact of GRD is well demonstrated by the most
common and best understood form: Autosomal Dominant
Polycystic Kidney Disease (ADPKD). ADPKD has a popu-
lation prevalence of 1/400-800 and is the most common
potentially lethal genetic disease in humans [9]. In
Australia and New Zealand, ADPKD is the primary renal
diagnosis in 6 % of the 12,968 prevalent dialysis patients
and the fourth most common cause for dialysis commence-
ment [10, 11]. Effective medical therapies for this condition
are on the cusp of clinical translation after several decades
of research, which initially elucidated the genetic aetiology
of ADPKD, then explained its pathogenesis, and finally
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enabled translational applications via clinical thera-
peutic trials [12]. ADPKD, however, represents less than
half of the estimated cases of GRD with many other
renal diseases being unidentified and incompletely
understood. Studies aiming at the detailed phenotypic
description and explanation of these other and often
very rare forms of GRD, are needed.
Enormous progress has been achieved in the field of
molecular genetics and genomics since the discovery of
deoxyribose nucleic acid (DNA) in 1953 [13]. The emer-
gence of massively parallel sequencing (MPS) from ap-
proximately 2005 [14] has arguably been the next greatest
advance since the development of Sanger sequencing in
the late 1970s [15, 16]. Next generation sequencing (NGS)
collectively describes these recently-developed genetic
technologies that enable rapid and cost effective sequen-
cing of large amounts of DNA. While sequencing of the
first human genome took over 10 years and required an
international collaboration at the approximate cost of
USD $3 billion [17], NGS now allows a human genome to
be sequenced in days at the cost of only $1–2,000 [18].
Whole exome sequencing (WES) is a variation on whole
genome sequencing (WGS) that allows for targeted se-
quencing of only the approximately 1.5 % of the human
genome that contains protein-coding genes, reducing
costs even further [19].
NGS facilitates rapid identification of disease-causing
genetic variants in patients with a suspected Mendelian
disorder. This utility was first proven by the discovery of
the gene involved in causing Freeman-Sheldon syndrome
[20]. With reduced cost and time, WES has become the
preferred initial method for disease gene identification in
small pedigrees, replacing previous methods, such as
linkage analysis and association studies. By 2012, more
than 100 causative genes had been identified by means
of WES [14]. WES is now able to elucidate the causal
mutations in nearly 50 % of patients thought to have a
genetic condition [21–23]. This diagnostic yield is fur-
ther optimised when family-based studies such as the
trio/family-based approach are employed [24]. In neph-
rology, NGS has identified disease-causing mutations
responsible for atypical haemolytic uremic syndrome
[25, 26], steroid-resistant nephrotic syndrome [27–29]
and nephronophthisis [30–39]. However, the resolution
within which any base change can be identified using this
technique results in the identification of large numbers of
variations, not all of which are pathogenic. Hence, it is
now more critical than ever to validate the pathogenicity
of any novel genetic variant. This may include appropriate
Mendelian segregation and genotype/phenotype correl-
ation via some form of biological validation.
With the advent of reprogramming of adult cells to a
pluripotent state, termed induced pluripotent stem cells
(iPSC), clinicians now have an opportunity to differentiate
cells from the patient in question into relevant tissue types
and in vitro [40]. Patient-specific iPSC differentiation
allows for more effective modelling of the patient’s own
disease [41–44]. For renal disease, this is a challenge as
the kidney is an architecturally and functionally complex
organ at both a microscopic and macroscopic level. How-
ever, recent studies have reported the directed differenti-
ation of iPSC to podocytes [45], tubular structures [46, 47]
and self-organising renal organoids [48], providing a po-
tential in vitro model system with which to validate novel
genetic findings in GRD patients. This also provides the
potential to better understand underlying pathology with
the aim of developing new treatments.
Recent advances in genetic sequencing technology
have resulted in remarkable improvements in the
speed, throughput and cost of sequencing all, or part,
of an individual’s genome. While it would appear feas-
ible to apply these new technologies to kidney disease,
a clinical protocol is required to guide patient identifi-
cation and recruitment, ethical acquisition of material,
and appropriate counselling whilst coupling this with
NGS for the identification of novel mutations and iPSC
validation to discover the genetic basis for rare genetic
diseases. The need for patients to be informed of out-
comes must also be addressed. We hypothesize that
emerging high-throughput sequencing technologies
will lead to the rapid identification of novel causative
genes in GRD and propose a study to begin realising
this potential within Australia.
Methods
Study aim
This study aims to discover the genetic basis for disease
in a cohort of patients thought clinically to have a gen-
etic disorder causing renal dysfunction or disease. The
cohort will be selected based upon family history and
phenotype strongly suggesting a genetic aetiology and
in whom routine genetic testing is not available, not
feasible or has not identified a mutation/s in currently
known genes. Our hypothesis is that we will be able
to identify the disease-causing mutations in a propor-
tion of these participants.
Study design
This is a translational study based at Royal Brisbane and
Women’s Hospital (RBWH) and the University of
Queensland (UQ) to discover, validate and explain new
genetic causes for inherited kidney disease where inves-
tigation for known genes has been unsuccessful or is
unavailable. Participants will be recruited from patients
attending the RBWH Conjoint Renal Genetics and
Inherited Kidney Disease Clinics, as part of standard
clinical care (Fig. 1).
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Ethical considerations
The RBWH Human Research and Ethics Committee
(approval HREC/14/QRBW/34), the UQ Medical Research
Ethics Committee (approval 2014000453) and the Chil-
dren’s Health Queensland Hospital and Health Service
Human Research and Ethics Committee (approval HREC/
15/QRCH/126), reviewed and approved the study.
Target population
This study involves two groups of participants:
1) An affected individual whose family history and/or
phenotype strongly suggests a genetic aetiology and
in whom routine genetic testing:
a) Is not clinically available
b) Is not feasible given the suspected disorder
has high genetic heterogeneity, or
c) Has already failed to arrive at a diagnosis
2) First degree and appropriate relatives of participants
of group 1.
Patient identification and screening
Patients referred to the RBWH Kidney Health Service,
RBWH Conjoint Renal Genetics Clinic and/or Genetic
Health Queensland (RBWH) will be identified as potential
research participants by their treating nephrologist and/or
clinical geneticist.
Once a suitable individual from the target popula-
tion is identified and consent obtained by the treating
clinician, their first-degree relatives will be invited to
participate in the study by consented individuals. The
research team will then be available to discuss and
provide full information about the study to the first-
degree relatives and offer them the opportunity to
participate, also by informed consent.
Patient/participant inclusion
In most cases inclusion in this study will require the
participation of the patient and both parents. How-
ever, in some cases a combination of factors including
the structure of the family pedigree, the suspected
mode of inheritance, and information available re-
garding the specific disease may provide the required
level of genetic information or require additional or
alternate family members to be included in the study,
and therefore warrant inclusion in the study. This will
be determined on a case-by-case basis by the princi-
pal investigators.
Fig. 1 Study flow diagram
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Patient/participant exclusion
The criteria for participant exclusion include unwilling-
ness to participate in the study and an insufficient number
of direct relatives willing/able to participate in the study.
Patient/participant withdrawal
Participants may be withdrawn from the study in the
following circumstances:
 Withdrawal at participant request. All participants
have the right to withdraw from the study at any
point in time. If a participant withdraws from the
study the analysis of their DNA and genetic
information will cease at that point. DNA samples
and any sequenced genomic data generated will be
destroyed.
 Withdrawal due to diagnosis from standard care. If a
specific genetic diagnosis becomes available during
the course of the study, the patient and the family will
be withdrawn from the study. If the pathobiology of
this diagnosis is not known or unclear, the participant
may be offered the opportunity to continue with iPSC
validation of the specific genetic diagnosis without
participation in NGS.
Participant identifiers
Upon recruitment, all participants will be assigned a
unique identifier for the purposes of this study. A con-
fidential database, maintained on a Queensland Health
(QH) server, will link participant identifying informa-
tion and their study identifier code. Study team mem-
bers from The University of Queensland will receive all
samples and case details anonymously, with the excep-
tion of the unique identifier. Only the clinical service
will know the identity of the patient samples.
DNA sample isolation
Peripheral blood is the preferred source of DNA for this
study due to the relative high quality, reliability and yield
of DNA compared to extractions from other tissues.
Blood samples will be collected by a trained phlebotom-
ist and DNA will be extracted by Pathology Queensland.
In some cases DNA samples will be required from a
tissue other than blood in specific instances, for example,
when validating the presence of mosaicism in a given indi-
vidual. In these cases a buccal (cheek) cell swab or saliva
sample will be taken by the treating nephrologist or clin-
ical geneticist. Buccal samples will be taken using Qiagen
Gentra Puregene Buccal Cell Kits (or equivalent) and
saliva samples will be taken using Oragene saliva DNA
collection kits.
Summary of clinical data, family structure and family history
The treating clinician of each affected index participant
will prepare a summary of the clinical features of the
participant, the family structure and any relevant family
history. This information is required to make informed
evaluations of the genetic variant data derived from each
family. This summary will not include any identifying
information other than participant study identifier codes.
This clinical summary will be provided to the research
team when DNA samples are provided.
DNA sequencing
Participant DNA samples will be sequenced using one or
more next generation sequencing technologies. Participant
samples may undergo whole genome sequencing, whole
exome sequencing and/or targeted re-sequencing of
restricted gene panels. The sequencing method will be
customised depending on the clinical presentation of the
condition and identity of any suspected candidate genes.
It is expected that exome sequencing will be the predom-
inant technique used to assess participant DNA due to the
favourable equipoise between coverage of the genome and
cost. Whole genomes will be sequenced to a minimum
depth of 30× reads average coverage depth while exomes
will be sequenced to a minimum depth such that >80 % of
targeted regions are sequenced to a depth greater than
20× reads.
Sequence analysis
DNA sequence data will be analysed from all participat-
ing members of a family in parallel. Comprehensive
quality control metrics are derived for each sample to
ensure the quality of the sequence data. All sequence
reads are compared to the human reference sequence
and used to identify variant positions where the partici-
pant DNA is different from the reference genome. Each
variant position within a family is then evaluated based
on its likelihood to contribute to the disease of the af-
fected individual/s. This assessment will be augmented
and assisted by the Variant Assessment Tool [49–51],
an internal software tool that integrates family genetic
variant segregation details with external referenced
information sources such as the frequency of the allele
in published control populations, the predicted impact
of the variant on protein coding sequences and genes
known to be associated with genetic disorders.
Reporting of findings
At the completion of the analysis, the findings will be re-
ported to the RBWH Kidney Health Service and RBWH
Conjoint Renal Genetics Clinic principal investigators.
These findings will then be presented to the treating
clinician after patient re-identification using their unique
study identifier. If candidate variants are identified that
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are believed to be involved in the patient’s renal disease,
they will be validated using Sanger sequencing in an
accredited clinical laboratory, if available. This informa-
tion will then be provided to the treating clinician for
discussion with their patient. If participants opted during
the informed consent process not to receive their results,
including any incidental findings discussed below, they
will be asked to confirm this decision when the results
of the research are available. Consent will be sought
from the participant should relatives need to be
approached regarding the research findings.
Validation using participant-derived iPSC lines
Identification of a predicted disease causing mutation via
any NGS approach requires validation, particularly if the
mutation is novel for this phenotype. This may include
identification of a similar mutation in another family,
validation of disease segregation within the affected fam-
ily or in vitro cell based analyses. This is critical in the
evaluation of any NGS-predicted mutation. In a limited
number of cases, and with patient consent, participant-
derived primary fibroblasts have been isolated from af-
fected individuals and clearly unaffected relatives for the
purpose of derivation of induced pluripotent stem cells.
Such iPSC can be used to generate specific kidney cell
types [46–48]. Comparisons will be made between lines
derived from the patient and the unaffected relative to
partially control for variations due to the underlying
genetic background. This requires the collection of fibro-
blasts (skin cells), which can be cultured as a primary cell
line, from the proband and an unaffected relative. These
cell lines will only be used for direct functional assessment
of the participants’ genetic variants or where the specific
inherited kidney disease’s pathobiology is unknown or in-
completely understood. The cell lines will not be used for
commercial purposes and will not be shared with third
parties not directly involved in this study.
After obtaining specific participant consent, medical
staff will obtain skin samples using a punch or shave bi-
opsy, or during a surgical procedure should a participant
be having surgery for an unrelated reason. Fibroblast cul-
ture will be undertaken according to established protocol
[52]. Blood [53], urine [54] or buccal swab samples may
also or alternatively be used to obtain a participant sam-
ple. Samples will be labelled with participant study unique
identifier codes and transferred directly to the research
laboratories for fibroblast and iPSC culture.
iPSC will be created from cultured patient cells with
non-integrative reprogramming using Sendai virus trans-
fection [55]. Subsequent differentiation to self-organising
renal progenitors, structures and organoids will be
undertaken [48]. A minimum of three clones from each
participant (both affected patient and unaffected relative)
will be assessed for disease phenotypes, to account for
interclonal differences. Additional differentiation to other
tissue types of relevance to the presentation of the
participant will be performed as appropriate depend-
ing on the variant/s discovered and the participant
phenotype revealed in the summary of clinical infor-
mation accompanying the participant study unique
identifier code. This is anticipated to include but not
be limited to neural, retinal, hepatic, pulmonary and
osseous tissues.
Participants may decline to provide skin, blood, urine
or buccal swab samples; this will not affect their ability
to participate in the genetic sequencing component of
this study.
Disclosure of results
Results will be returned to the treating clinician who will
be able to re-identify the participant. The evaluation of the
research finding and disclosure to the patient and their
family will be the responsibility of the treating clinician.
The research findings may include a result of uncertain
significance or an uninformative result. Patients will be
counselled on the potential clinical implications of the re-
sults, as is standard clinical care. Further testing in a
clinically-accredited laboratory may need to take place
should the result be required for clinical management.
The study may reveal results that are significant to
family members. The research results will be provided
to the patients in the clinic. They will be counseled, if
relevant, on the need to inform their relatives of their
results. These patients will be provided with a family let-
ter they can send to their relatives. Relatives considered
at risk can then obtain a referral to the RBWH Kidney
Health Service, RBWH Conjoint Renal Genetics Clinic
or Genetic Health Queensland (or their local nephrol-
ogy or clinical genetics service) for counseling. Subse-
quent clinical genetic testing (cascade testing) may be
arranged for these relatives.
Due to the nature of this analysis, any non-paternity/
maternity present within a participating family will be
detected during our analysis. In accordance with the
Australian National Health and Medical Research
Council guidelines (Medical Genetic Testing Informa-
tion for Health Professionals 2010 [56]) non-paternity
or non-maternity would be disclosed in only the most
exceptional circumstances, as this may cause serious
harm to individuals and families.
Results could potentially preclude participants from
insurance such as life, income protection, and mortgage
protection. It is an applicant’s responsibility to declare
any known health information about themselves and
their genetic relatives in insurance applications. This
topic is covered in detail during the initial consent
process.
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Incidental findings
One or more disease-associated genetic variants that are
not related to the genetic condition being investigated may
be identified in a participant. These are termed “incidental
findings”. An example of this could be a gene mutation as-
sociated with an increased risk of a serious health problem,
such as cancer. There is growing recognition of particular
genes for which there is consensus that mutations in
those genes may represent clinically significant inci-
dental findings [57, 58]. This study has a very small
chance of discovering an individual/family has a herit-
able disposition to an unrelated disorder (eg, cancer).
The frequency of such actionable unintended findings
is estimated to be less than 3 % [59, 60]. Participants
will undergo a rigorous prospective consent process
informing them of this, with the option of opting out
from receiving such information in their study results.
If a genetic variant is discovered that the research team
believes may be medically relevant for one or more of the
participants, and the participant has consented to receive
such incidental findings, it will be referred to an expert
panel for review. The panel will consist of one clinical
nephrology principal investigator (AM, HH or delegate),
one person expert in next generation sequencing bioinfor-
matics (RT, CS or delegate), one coopted clinical geneticist
(CP, MG, JM or delegate), and one coopted medical spe-
cialist in the field to which the potential disease pertains
(eg oncologist, gastroenterologist). The committee will
consider the incidental finding and determine if (a) the
finding confers a high risk of disease in the future; and (b)
interventions such as surveillance are available to decrease
the risk of morbidity/mortality. Should both criteria be
fulfilled, the result will be presented to the participant if
they had consented to learn of such information.
All participants who have previously declined to be in-
formed of incidental findings will be asked again if this
is still their wish, regardless of whether an incidental
finding has been uncovered or not. All participants are
informed of this at the time of initial consent.
Discussion
Advances in NGS bring within reach the promise of
identifying genetic changes associated with the majority of
heritable diseases. The discovery of novel disease-causing
genes and mutations for a specific condition results in
substantial potential benefits to both the patient/family as
well as other patients thought to have that condition
(Table 1).
Recently Simons et al. have used a combination of
WES and WGS to study the genetic basis of a cohort of
patients with leukodystrophy; a group of rare disorders
characterized by dysfunction of the white matter of the
brain. This approach has described several new diseases,
including “hypomyelination with brain stem and spinal
cord involvement and leg spasticity”, due to autosomal
recessive mutations in the aspartyl-tRNA synthetase
gene DARS [51], and “leukoencephalopathy hypomyeli-
nation with atrophy of the basal ganglia and cerebellum”
due to de novo mutation in the gene TUBB4A [50]. This
group has also recently identified the previously unknown
genetic cause of Temple-Baraitser syndrome to be due to
mutations in KCNH1 [49]. Our study utilises and builds
upon this clear skillset and expertise to discover and
describe new genetic causes of GRD.
There are examples however where disease-causing
genotypes are recalcitrant to or are unexplored by the
application of NGS, such as in Autosomal Dominant
Tubulointerstitial Disease (formerly known as Medullary
Cystic Kidney Disease type 1 [61, 62] and type 2 [63–66]).
Furthermore, whole exome or genome approaches, as
used in gene discovery experimentation, are inaccurate in
several relatively common and well-described diseases
such as ADPKD [67], which instead require a tailored
MPS approach [67, 68]. On the other hand, the power of
diagnostic NGS approaches have been exemplified in
Alport Syndrome [69], particularly with respect to identi-
fying mosaicism [70] and unclear clinicopathological asso-
ciations [71–73].
Whilst utilising such rapidly evolving genomic ap-
proaches in clinical practice offers significant potential
benefits [74], it also creates potential complications. The
perceived benefits of this technology have become a
source of concern, particularly with regard to unintended
or incidental findings [75–82]. This is further exacerbated
by the variety of legal and regulatory paradigms within a
globalised society [83–89]. The frequency of such action-
able unintended findings in comparable studies to ours
has been less than 3 % [59, 60]. If the criteria for “action-
ability” is liberalised this may be higher [90, 91], though
still of potential personal and cost benefit [92].
One cannot presently pretend to have durable or all-
encompassing answers to the conundrums posed by
incidental genetic findings. Prudence and increased em-
phasis on informed consent and appropriate reporting
Table 1 Potential benefits of identifying novel disease-causing
mutations in kidney disease
• Achieving a diagnosis
• Precise identification of the molecular defect for genotype/phenotype
correlations
• Accurate genetic counselling and, where appropriate, subsequent
prenatal testing
• Accurate cascade testing to identify risks to other relatives
• Enhanced gene lists for future diagnostic testing
• Elucidation of new genetic conditions/syndromes, improving diagnosis
in further individuals
• Improved understanding of the molecular pathology, leading to the
development of more effective therapies
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may however provide a way forward [93–95]. A less
definable answer is that local multidisciplinary teams pro-
vide broad opportunities to consider such challenges from
a plurality of perspectives thus improving clinical transla-
tion, maximising benefits, minimising risk and providing
durable clinical supports. Accordingly these have been
actively integrated into the study we propose.
Functional validation of novel genetic discoveries in
rare diseases poses significant challenges. iPSC technolo-
gies, as first described in 2006 [40], provide opportun-
ities and unique strategies to address this. Patient-
derived iPSC approaches to create, identify, describe and
differentiate renal progenitors and self-organising orga-
noids [48] provide the opportunity to undertake such
validation via patient-derived iPSC “disease in a dish”
studies. Further experience with other tissue phenotypes,
as may be encountered in inherited syndromic multisys-
tem disease, will be utilised. Specifically, Wolvetang
et al. have successfully modelled human genetic disease
(Ataxia-Telangiectasia and Down syndrome) using pa-
tient derived iPSC in studies that have further described
the cellular and tissue pathobiology underpinning how
genetic aetiology translates into complex clinical pheno-
types [96, 97]. The application of CRISPR-Cas9 technol-
ogy [98–100] to introduce or correct mutations in such
cellular or organoid disease models [101–103] may also
be required and employed. We propose that this coor-
dinated approach to in vitro patient-derived iPSC study
will enable a greater ability to characterize rare GRD
at a cellular level and presents a logical pathway and
opportunity for functional validation of genetic vari-
ants discovered.
In summary, we describe a collaborative research ap-
proach to the elucidation of the underlying cause of previ-
ously refractory forms of GRD. The protocol requires
integration between clinicians and scientists and the appli-
cation of state-of-the-art genetic and stem cell technolo-
gies within diagnostic proximity of the patient in order to
reduce the number of cases of unknown genetic causation.
There remain significant challenges to delivering new
knowledge to the clinician and patient, including the bio-
informatics challenges of identifying a causative mutation
out of the >60,000 variations likely to be detected in any
individual, and the technical obstacles to the functional
analysis of iPSC-derived organoids. If adopted more
broadly, this approach can potentially translate into opti-
mised diagnostic, therapeutic and clinical outcomes for
affected patients.
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